What is GenePeeks?
GenePeeks operates at the intersection of genomics and reproductive health, offering a patented technology that digitally simulates the genetic interactions of potential parents. By analyzing thousands of Virtual Progeny, the platform identifies inherited disease risks that may not be detectable through conventional screening methods. Founded by CEO Anne Morriss and CSO Lee Silver, Ph.D., the company aims to empower families with critical information to protect future generations from serious genetic conditions. GenePeeks provides physician-ordered testing and analytics through its dedicated clinical laboratory, positioning itself as a leader in predictive genetic diagnostics.
How much funding has GenePeeks raised?
GenePeeks has raised a total of $38.8M across 5 funding rounds:
Series A
$5.3M
Debt
$3M
Private Equity
$10M
Other Financing Round
$4.5M
Series B
$16M
Series A (2012): $5.3M with participation from Columbus Nova Technology Partners
Debt (2014): $3M led by Horizon Technology
Private Equity (2016): $10M, investors not publicly disclosed
Other Financing Round (2017): $4.5M featuring Bridge Bank
Series B (2017): $16M backed by Alexandria Real Estate Equities, 5AM Ventures, Alta Partners, and Columbus Nova Technology Partners
Key Investors in GenePeeks
Columbus Nova Technology Partners
Columbus Nova Technology Partners is an investment firm that focuses on technology companies. Their involvement suggests a strategic interest in GenePeeks' innovative computational genomics platform and its potential for disruption in the healthcare technology market.
Horizon Technology
Horizon Technology Finance provides structured debt financing to development-stage companies, particularly in technology and life sciences. Their participation indicates confidence in GenePeeks' business model and its capacity for growth and repayment through venture lending.
Alexandria Real Estate Equities
Alexandria Real Estate Equities is a real estate investment trust specializing in properties for the life sciences industry. Their investment in GenePeeks suggests a strategic alignment with companies at the forefront of biotech and health innovation, potentially providing infrastructure or strategic partnerships.
What's next for GenePeeks?
The recent major enterprise-level funding and strategic investment signal a pivotal growth phase for GenePeeks. This capital infusion is anticipated to accelerate the company's research and development initiatives, enhance its proprietary platform, and expand its market reach within the healthcare and biotechnology sectors. With a focus on innovation in computational genomics, GenePeeks is poised to further solidify its position as a key player in the field of inherited disease risk assessment, potentially leading to broader adoption of its advanced screening solutions by healthcare providers and consumers alike.
See full GenePeeks company page
